News & Media

Press Releases

Amolyt Pharma Announces Research Collaboration with PeptiDream

December 8, 2020

Amolyt Pharma Announces Research Collaboration with PeptiDream Download a PDF copy of this press release: EN FR Amolyt and Peptidream will collaborate to optimize and …

Download a PDF: EN or FR

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism

October 14, 2020

LYON, France, and NEWTON, MA, October 14, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global clinical-stage company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the first subject in the Phase 1 clinical trial for AZP-3601 has been dosed.

Download a PDF: EN or FR

Amolyt Pharma Appoints Pierre Legault as a Director and Chairman of its Board of Directors as Company Transitions into Clinical Stage

June 8, 2020

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced the appointment of Pierre Legault, MBA, CPA as director and chairman of its board of directors…

Download a PDF: EN or FR

Presentations

AZP-3404

AZP-3404, a Peptide Analog of IGFBP-2, Induces Weight Loss and Improves Glucose Metabolism in Leptin-Resistant db/db Mice. ENDO 2021.

Written by

jpoly4

Download a PDF: EN or FR

AZP-3601

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

Written by

jpoly4

Download a PDF: EN or FR

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

Written by

jpoly4

Download a PDF: EN or FR

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Written by

jpoly4

Download a PDF: EN or FR

Upcoming events

ENDO 2021

Date: March 20-23, 2021

Learn more about the conference »

News & Media

Press Releases

Amolyt Pharma Announces Research Collaboration with PeptiDream

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism

Amolyt Pharma Appoints Pierre Legault as a Director and Chairman of its Board of Directors as Company Transitions into Clinical Stage

Presentations

AZP-3404, a Peptide Analog of IGFBP-2, Induces Weight Loss and Improves Glucose Metabolism in Leptin-Resistant db/db Mice. ENDO 2021.

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Upcoming events

Social Updates

TWITTER